Global Dendritic Cell Cancer Vaccine Immunotherapy Market by Route of Administration ( Intravenous, Intranodal, Intralymphatic, Intradermal, Subcutaneous); By Clinical Trial Phase (Preclinical and Phase I, Phase II , Phase III, Late Phase Clinical Research); By End-User (Research Centres, Pharmaceutical Companies, Hospitals and Clinics, Others); By Application (Adults, Kids); By Cancer Type (Breast Cancer, Pancreatic Cancer, Oesophageal Cancer, Prostate Cancer, Glioblastoma, Colorectal Cancer, Melanoma, Liver Cancer, Renal Cancer, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia(Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia) Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
The global dendritic cell cancer vaccine immunotherapy market for cancer patients is estimated to be driven by three major developments - advancement in the technology, ground-breaking research on action of the dendritic cells against the cancer cells and massive consumerization of health through improved access to patient data provided by AI (artificial intelligence). Unlike existing methods like chemotherapy or radiation therapy which have more disadvantages than advantages, dendritic cell vaccine immunotherapy is estimated to burst that bubble. Clinical results gained through the therapy have led to a reduction in the hype generated by old and traditional therapies, resulting in an increase in the demand for items that are already in the market.
The market's future is expected to disclose long-term viability of clinical responses, as well as a considerable improvement in the market's broad spectrum development. The downward pressure on the pricing of the developed drugs is estimated to change the upsetting of the market, greatly emphasising the market expansion and acceptance at an international level. Along with these, the global dendritic cell cancer vaccine immunotherapy market is also observing several major players emerging for the overall development of the market. According to the dendritic cell vaccine immunotherapy market report, the therapy's introduction into the market has put an end to the long wait for a therapeutic capable of efficiently modifying dendritic cells and targeting them against cancer cells. The global cancer healthcare business was in desperate need of a viable therapy that would give patients a higher five-year survival rate, less side effects, and greater targeting ability of the altered cells, among other benefits.
In terms of revenue, the global dendritic cell cancer vaccine immunotherapy market is growing at a CAGR of 14.4% over the forecast period (2021 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue & Forecast, (US$ Million), 2015 – 2029
By Type Outlook:
Based on cancer type, global dendritic cell cancer vaccine immunotherapy Market has been segmented into lung cancer, breast cancer, pancreatic cancer, oesophageal cancer, prostate cancer, glioblastoma, colorectal cancer, melanoma, liver cancer, renal cancer and others. Lung cancer with 1.76 million yearly deaths followed by colorectal cancer: 862,000 deaths dominates the global dendritic cell cancer vaccine immunotherapy market in 2020. Growth in tobacco consumption, alcohol, obesity, sedentary lifestyle and environmental factors also contribute to the increase in cancers. The overall living settings of the population across the world has improved and that has also led to a larger sedentary workforce, which has access to high calorie diet, indirectly affecting the rise in numbers.
By Route of Administration Outlook:
Based on technique, the global dendritic cell cancer vaccine immunotherapy market has been segmented into intravenous, intranodal, intra-lymphatic, intradermal, subcutaneous segments. Immunotherapy vaccines can be injected into a vein (intravenously), injected into the skin (subcutaneously), or injected into a muscle (intramuscularly). Certain types of immunotherapy can be administered directly to the tumor's location in the bodily cavity. Immunotherapy clinical trials, like other forms of cancer treatment, are currently being done to enhance treatment for people with a variety of cancers. For a variety of reasons, patients are encouraged to take part in relevant immunotherapy research studies. For starters, individuals who take part in a clinical trial may be among the first to benefit from novel medications before they become publicly available. Immunotherapy research trials may also offer new hope to patients who have failed to respond to standard treatments.
By Clinical Trial Phase Outlook:
Based on clinical trial phase, the global dendritic cell cancer vaccine immunotherapy market is divided into preclinical and phase i, phase ii, phase iii, late phase clinical research. The COVID-19 pandemic has the potential to have an economic impact and repercussions across a wide range of businesses, including pharmaceutical and biotech. The expanding number of cancer patients, the demand for tailored medications, and the pharmaceutical industry's significant R&D spending in oncology are all driving the market forward. The impact of COVID-19 on the oncology clinical trials market was negative because cancer clinical trials number was decreased to prevent the spread of the virus. For instance, according to a research article by Emma Wilkinson published in the Journal - The Lancet February 2021, there was a 60% decrease in new cancer clinical trials and biological therapies during the COVID-19 pandemic 2020. Improvement in COVID-19 recovery cases will further foster the growth for clinical trials in the future, which will drive growth of global dendritic cell cancer vaccine immunotherapy market.
By Application Outlook:
Based on application, the global dendritic cell cancer vaccine immunotherapy market is divided into kids and adults. Cancer continues to be a major cause of morbidity and mortality in children and is the second leading cause of death before adolescence. The prognosis of paediatric cancer has markedly improved in recent years. Therapies for paediatric cancer, however, often result in significant toxicity leading to lifelong disability. In U.S., for example, approximately 15,780 children age 0–19 years are diagnosed with cancer each year. Immunotherapy harnesses the ability of the immune system to combat infection and neoplasia and has emerged as a promising treatment modality for many paediatric and adult malignancies Therefore, the advancement in dendritic cells therapy will drive the cancer immunotherapy market demand.
Region Outlook:
Based on region, North America has emerged as the largest regional dendritic cell cancer vaccine immunotherapy market in 2020. The United States is predicted to lead the market in the North American region, owing to factors such as increased R&D spending, rising government assistance, and rising demand for medication development. Furthermore, as the number of cancer cases rises, clinical trials are projected to rise in the coming years. For example, according to the National Clinical Trials (NCT) registry, as of 2021, in the United States, Canada, and Mexico, there have been around 38,445, 5,692, and 726 clinical trials related to cancer across different phases of development. As a result of the aforementioned reasons, market growth in the North American region is predicted to remain at a dominant position over the forecast period.
Competitive Landscape
The report provides both, qualitative and quantitative research of global dendritic cell cancer vaccine immunotherapy market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the key players operating in the global dendritic cell cancer vaccine immunotherapy market are:
- Activartis GmbH
- Bellicum Pharmaceuticals
- Dendreon Corporation
- Elios Therapeutics
- Immunicum AB
- Immunicum AB
- JW Creagene
- Medigene AG
- THERAVECTYS
- Other Market Participants
Global Dendritic Cell Cancer Vaccine Immunotherapy Market:
By Route of Administration
- Intravenous
- Intranodal
- Intralymphatic
- Intradermal
- Subcutaneous
By Clinical Trial Phase
- Preclinical and Phase I
- Phase II
- Phase III
- Late Phase Clinical Research
By Application
- Adults
- Kids
By Cancer Type
- Breast Cancer
- Pancreatic Cancer
- Oesophageal Cancer
- Prostate Cancer
- Glioblastoma
- Colorectal Cancer
- Melanoma
- Liver Cancer
- Renal Cancer
- Others
By End-User
- Research Centres
- Pharmaceutical Companies
- Hospitals and Clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Dendritic Cell Cancer Vaccine
Immunotherapy Market
6. Market Synopsis:
Dendritic Cell Cancer Vaccine Immunotherapy Market
7. Dendritic Cell Cancer Vaccine Immunotherapy Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in
Dendritic Cell Cancer Vaccine Immunotherapy Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Dendritic Cell Cancer Vaccine Immunotherapy
Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Dendritic Cell Cancer Vaccine Immunotherapy Market
8. Global Dendritic Cell Cancer Vaccine Immunotherapy Market
Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn)
8.2. Global
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
8.2.1. Intravenous
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2020
8.2.1.3. Market Forecast, 2021 - 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 - 2020
8.2.1.5.1.2. Market
Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2020
8.2.1.5.2.2. Market
Forecast, 2021 - 2029
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2020
8.2.1.5.3.2. Market
Forecast, 2021 - 2029
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2020
8.2.1.5.4.2. Market
Forecast, 2021 - 2029
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 - 2020
8.2.1.5.5.2. Market
Forecast, 2021 - 2029
8.2.2. Intranodal
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 - 2020
8.2.2.5.1.2. Market
Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2020
8.2.2.5.2.2. Market
Forecast, 2021 - 2029
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2020
8.2.2.5.3.2. Market
Forecast, 2021 - 2029
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2020
8.2.2.5.4.2. Market
Forecast, 2021 - 2029
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 - 2020
8.2.2.5.5.2. Market
Forecast, 2021 - 2029
8.2.3. Intralymphatic
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2020
8.2.3.3. Market Forecast, 2021 - 2029
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 - 2020
8.2.3.5.1.2. Market
Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2020
8.2.3.5.2.2. Market
Forecast, 2021 - 2029
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2020
8.2.3.5.3.2. Market
Forecast, 2021 - 2029
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2020
8.2.3.5.4.2. Market
Forecast, 2021 - 2029
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 - 2020
8.2.3.5.5.2. Market
Forecast, 2021 - 2029
8.2.4. Intradermal
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2020
8.2.4.3. Market Forecast, 2021 - 2029
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2015 - 2020
8.2.4.5.1.2. Market
Forecast, 2021 - 2029
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2020
8.2.4.5.2.2. Market
Forecast, 2021 - 2029
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2020
8.2.4.5.3.2. Market
Forecast, 2021 - 2029
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2020
8.2.4.5.4.2. Market
Forecast, 2021 - 2029
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2015 - 2020
8.2.4.5.5.2. Market
Forecast, 2021 - 2029
8.2.5. Subcutaneous
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2020
8.2.5.3. Market Forecast, 2021 - 2029
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North
America
8.2.5.5.1.1. Market
Estimation, 2015 - 2020
8.2.5.5.1.2. Market
Forecast, 2021 - 2029
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 - 2020
8.2.5.5.2.2. Market
Forecast, 2021 - 2029
8.2.5.5.3. Asia
Pacific
8.2.5.5.3.1. Market
Estimation, 2015 - 2020
8.2.5.5.3.2. Market
Forecast, 2021 - 2029
8.2.5.5.4. Middle
East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 - 2020
8.2.5.5.4.2. Market
Forecast, 2021 - 2029
8.2.5.5.5. Latin
America
8.2.5.5.5.1. Market
Estimation, 2015 - 2020
8.2.5.5.5.2. Market
Forecast, 2021 - 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By Route
of Administration
9. Global Dendritic Cell Cancer Vaccine Immunotherapy Market
Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial Phase
9.2.1. Preclinical
and Phase I
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2020
9.2.1.3. Market Forecast, 2021 - 2029
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 - 2020
9.2.1.5.1.2. Market
Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2020
9.2.1.5.2.2. Market
Forecast, 2021 - 2029
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2020
9.2.1.5.3.2. Market
Forecast, 2021 - 2029
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2020
9.2.1.5.4.2. Market
Forecast, 2021 - 2029
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 - 2020
9.2.1.5.5.2. Market
Forecast, 2021 - 2029
9.2.2. Phase II
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 - 2020
9.2.2.5.1.2. Market
Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2020
9.2.2.5.2.2. Market
Forecast, 2021 - 2029
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2020
9.2.2.5.3.2. Market
Forecast, 2021 - 2029
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2020
9.2.2.5.4.2. Market
Forecast, 2021 - 2029
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 - 2020
9.2.2.5.5.2. Market
Forecast, 2021 - 2029
9.2.3. Phase
III
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2020
9.2.3.3. Market Forecast, 2021 - 2029
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 - 2020
9.2.3.5.1.2. Market
Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2020
9.2.3.5.2.2. Market
Forecast, 2021 - 2029
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2020
9.2.3.5.3.2. Market
Forecast, 2021 - 2029
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2020
9.2.3.5.4.2. Market
Forecast, 2021 - 2029
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 - 2020
9.2.3.5.5.2. Market
Forecast, 2021 - 2029
9.2.4. Late
Phase Clinical Research
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2020
9.2.4.3. Market Forecast, 2021 - 2029
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2015 - 2020
9.2.4.5.1.2. Market
Forecast, 2021 - 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2020
9.2.4.5.2.2. Market
Forecast, 2021 - 2029
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2020
9.2.4.5.3.2. Market
Forecast, 2021 - 2029
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2020
9.2.4.5.4.2. Market
Forecast, 2021 - 2029
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2015 - 2020
9.2.4.5.5.2. Market
Forecast, 2021 - 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Clinical Trial Phase
10. Global Dendritic Cell Cancer Vaccine Immunotherapy Market
Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
10.2.1. Breast
Cancer
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 - 2020
10.2.1.5.1.2. Market
Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2020
10.2.1.5.2.2. Market
Forecast, 2021 - 2029
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2020
10.2.1.5.3.2. Market
Forecast, 2021 - 2029
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2020
10.2.1.5.4.2. Market
Forecast, 2021 - 2029
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 - 2020
10.2.1.5.5.2. Market
Forecast, 2021 - 2029
10.2.2. Pancreatic
Cancer
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 - 2020
10.2.2.5.1.2. Market
Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2020
10.2.2.5.2.2. Market
Forecast, 2021 - 2029
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2020
10.2.2.5.3.2. Market
Forecast, 2021 - 2029
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2020
10.2.2.5.4.2. Market
Forecast, 2021 - 2029
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 - 2020
10.2.2.5.5.2. Market
Forecast, 2021 - 2029
10.2.3. Oesophageal
Cancer
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 - 2020
10.2.3.5.1.2. Market
Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2020
10.2.3.5.2.2. Market
Forecast, 2021 - 2029
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2020
10.2.3.5.3.2. Market
Forecast, 2021 - 2029
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2020
10.2.3.5.4.2. Market
Forecast, 2021 - 2029
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 - 2020
10.2.3.5.5.2. Market
Forecast, 2021 - 2029
10.2.4. Prostate
Cancer
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2020
10.2.4.3. Market Forecast, 2021 - 2029
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2015 - 2020
10.2.4.5.1.2. Market
Forecast, 2021 - 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2020
10.2.4.5.2.2. Market
Forecast, 2021 - 2029
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2020
10.2.4.5.3.2. Market
Forecast, 2021 - 2029
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2020
10.2.4.5.4.2. Market
Forecast, 2021 - 2029
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2015 - 2020
10.2.4.5.5.2. Market
Forecast, 2021 - 2029
10.2.5. Glioblastoma
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 - 2020
10.2.5.3. Market Forecast, 2021 - 2029
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North
America
10.2.5.5.1.1. Market
Estimation, 2015 - 2020
10.2.5.5.1.2. Market
Forecast, 2021 - 2029
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 - 2020
10.2.5.5.2.2. Market
Forecast, 2021 - 2029
10.2.5.5.3. Asia
Pacific
10.2.5.5.3.1. Market
Estimation, 2015 - 2020
10.2.5.5.3.2. Market
Forecast, 2021 - 2029
10.2.5.5.4. Middle
East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 - 2020
10.2.5.5.4.2. Market
Forecast, 2021 - 2029
10.2.5.5.5. Latin
America
10.2.5.5.5.1. Market
Estimation, 2015 - 2020
10.2.5.5.5.2. Market
Forecast, 2021 - 2029
10.2.6. Colorectal
Cancer
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2015 - 2020
10.2.6.3. Market Forecast, 2021 - 2029
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North
America
10.2.6.5.1.1. Market
Estimation, 2015 - 2020
10.2.6.5.1.2. Market
Forecast, 2021 - 2029
10.2.6.5.2. Europe
10.2.6.5.2.1. Market
Estimation, 2015 - 2020
10.2.6.5.2.2. Market
Forecast, 2021 - 2029
10.2.6.5.3. Asia
Pacific
10.2.6.5.3.1. Market
Estimation, 2015 - 2020
10.2.6.5.3.2. Market
Forecast, 2021 - 2029
10.2.6.5.4. Middle
East and Africa
10.2.6.5.4.1. Market
Estimation, 2015 - 2020
10.2.6.5.4.2. Market
Forecast, 2021 - 2029
10.2.6.5.5. Latin
America
10.2.6.5.5.1. Market
Estimation, 2015 - 2020
10.2.6.5.5.2. Market
Forecast, 2021 - 2029
10.2.7. Melanoma
10.2.7.1. Definition
10.2.7.2. Market Estimation and Penetration, 2015 - 2020
10.2.7.3. Market Forecast, 2021 - 2029
10.2.7.4. Compound Annual Growth Rate (CAGR)
10.2.7.5. Regional Bifurcation
10.2.7.5.1. North
America
10.2.7.5.1.1. Market
Estimation, 2015 - 2020
10.2.7.5.1.2. Market
Forecast, 2021 - 2029
10.2.7.5.2. Europe
10.2.7.5.2.1. Market
Estimation, 2015 - 2020
10.2.7.5.2.2. Market
Forecast, 2021 - 2029
10.2.7.5.3. Asia
Pacific
10.2.7.5.3.1. Market
Estimation, 2015 - 2020
10.2.7.5.3.2. Market
Forecast, 2021 - 2029
10.2.7.5.4. Middle
East and Africa
10.2.7.5.4.1. Market
Estimation, 2015 - 2020
10.2.7.5.4.2. Market
Forecast, 2021 - 2029
10.2.7.5.5. Latin
America
10.2.7.5.5.1. Market
Estimation, 2015 - 2020
10.2.7.5.5.2. Market
Forecast, 2021 - 2029
10.2.8. Liver
Cancer
10.2.8.1. Definition
10.2.8.2. Market Estimation and Penetration, 2015 - 2020
10.2.8.3. Market Forecast, 2021 - 2029
10.2.8.4. Compound Annual Growth Rate (CAGR)
10.2.8.5. Regional Bifurcation
10.2.8.5.1. North
America
10.2.8.5.1.1. Market
Estimation, 2015 - 2020
10.2.8.5.1.2. Market
Forecast, 2021 - 2029
10.2.8.5.2. Europe
10.2.8.5.2.1. Market
Estimation, 2015 - 2020
10.2.8.5.2.2. Market
Forecast, 2021 - 2029
10.2.8.5.3. Asia
Pacific
10.2.8.5.3.1. Market
Estimation, 2015 - 2020
10.2.8.5.3.2. Market
Forecast, 2021 - 2029
10.2.8.5.4. Middle
East and Africa
10.2.8.5.4.1. Market
Estimation, 2015 - 2020
10.2.8.5.4.2. Market
Forecast, 2021 - 2029
10.2.8.5.5. Latin
America
10.2.8.5.5.1. Market
Estimation, 2015 - 2020
10.2.8.5.5.2. Market
Forecast, 2021 - 2029
10.2.9. Renal
Cancer
10.2.9.1. Definition
10.2.9.2. Market Estimation and Penetration, 2015 - 2020
10.2.9.3. Market Forecast, 2021 - 2029
10.2.9.4. Compound Annual Growth Rate (CAGR)
10.2.9.5. Regional Bifurcation
10.2.9.5.1. North
America
10.2.9.5.1.1. Market
Estimation, 2015 - 2020
10.2.9.5.1.2. Market
Forecast, 2021 - 2029
10.2.9.5.2. Europe
10.2.9.5.2.1. Market
Estimation, 2015 - 2020
10.2.9.5.2.2. Market
Forecast, 2021 - 2029
10.2.9.5.3. Asia
Pacific
10.2.9.5.3.1. Market
Estimation, 2015 - 2020
10.2.9.5.3.2. Market
Forecast, 2021 - 2029
10.2.9.5.4. Middle
East and Africa
10.2.9.5.4.1. Market
Estimation, 2015 - 2020
10.2.9.5.4.2. Market
Forecast, 2021 - 2029
10.2.9.5.5. Latin
America
10.2.9.5.5.1. Market
Estimation, 2015 - 2020
10.2.9.5.5.2. Market
Forecast, 2021 - 2029
10.2.10. Others
10.2.10.1.
Definition
10.2.10.2.
Market Estimation and
Penetration, 2015 - 2020
10.2.10.3.
Market Forecast, 2021 - 2029
10.2.10.4.
Compound Annual Growth Rate
(CAGR)
10.2.10.5.
Regional Bifurcation
10.2.10.5.1. North
America
10.2.10.5.1.1. Market
Estimation, 2015 - 2020
10.2.10.5.1.2. Market
Forecast, 2021 - 2029
10.2.10.5.2. Europe
10.2.10.5.2.1. Market
Estimation, 2015 - 2020
10.2.10.5.2.2. Market
Forecast, 2021 - 2029
10.2.10.5.3. Asia
Pacific
10.2.10.5.3.1. Market
Estimation, 2015 - 2020
10.2.10.5.3.2. Market
Forecast, 2021 - 2029
10.2.10.5.4. Middle
East and Africa
10.2.10.5.4.1. Market
Estimation, 2015 - 2020
10.2.10.5.4.2. Market
Forecast, 2021 - 2029
10.2.10.5.5. Latin
America
10.2.10.5.5.1. Market
Estimation, 2015 - 2020
10.2.10.5.5.2. Market
Forecast, 2021 - 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
Cancer Type
11. Global Dendritic Cell Cancer Vaccine Immunotherapy Market
Analysis and Forecasts, 2021 – 2029
11.1. Overview
11.2. Global
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Application
11.2.1. Adults
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2020
11.2.1.3. Market Forecast, 2021 - 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2015 - 2020
11.2.1.5.1.2. Market
Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2020
11.2.1.5.2.2. Market
Forecast, 2021 - 2029
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2020
11.2.1.5.3.2. Market
Forecast, 2021 - 2029
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2020
11.2.1.5.4.2. Market
Forecast, 2021 - 2029
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2015 - 2020
11.2.1.5.5.2. Market
Forecast, 2021 - 2029
11.2.2. Kids
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2020
11.2.2.3. Market Forecast, 2021 - 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2015 - 2020
11.2.2.5.1.2. Market
Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2020
11.2.2.5.2.2. Market
Forecast, 2021 - 2029
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2020
11.2.2.5.3.2. Market
Forecast, 2021 - 2029
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2020
11.2.2.5.4.2. Market
Forecast, 2021 - 2029
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2015 - 2020
11.2.2.5.5.2. Market
Forecast, 2021 - 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By
Application
12. Global Dendritic Cell Cancer Vaccine Immunotherapy Market
Analysis and Forecasts, 2021 – 2029
12.1. Overview
12.2. Global
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By End-User
12.2.1. Research
Centres
12.2.1.1. Definition
12.2.1.2. Market Estimation and Penetration, 2015 - 2020
12.2.1.3. Market Forecast, 2021 - 2029
12.2.1.4. Compound Annual Growth Rate (CAGR)
12.2.1.5. Regional Bifurcation
12.2.1.5.1. North
America
12.2.1.5.1.1. Market
Estimation, 2015 - 2020
12.2.1.5.1.2. Market
Forecast, 2021 - 2029
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2015 - 2020
12.2.1.5.2.2. Market
Forecast, 2021 - 2029
12.2.1.5.3. Asia
Pacific
12.2.1.5.3.1. Market
Estimation, 2015 - 2020
12.2.1.5.3.2. Market
Forecast, 2021 - 2029
12.2.1.5.4. Middle
East and Africa
12.2.1.5.4.1. Market
Estimation, 2015 - 2020
12.2.1.5.4.2. Market
Forecast, 2021 - 2029
12.2.1.5.5. Latin
America
12.2.1.5.5.1. Market
Estimation, 2015 - 2020
12.2.1.5.5.2. Market
Forecast, 2021 - 2029
12.2.2. Pharmaceutical
Companies
12.2.2.1. Definition
12.2.2.2. Market Estimation and Penetration, 2015 - 2020
12.2.2.3. Market Forecast, 2021 - 2029
12.2.2.4. Compound Annual Growth Rate (CAGR)
12.2.2.5. Regional Bifurcation
12.2.2.5.1. North
America
12.2.2.5.1.1. Market
Estimation, 2015 - 2020
12.2.2.5.1.2. Market
Forecast, 2021 - 2029
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2015 - 2020
12.2.2.5.2.2. Market
Forecast, 2021 - 2029
12.2.2.5.3. Asia
Pacific
12.2.2.5.3.1. Market
Estimation, 2015 - 2020
12.2.2.5.3.2. Market
Forecast, 2021 - 2029
12.2.2.5.4. Middle
East and Africa
12.2.2.5.4.1. Market
Estimation, 2015 - 2020
12.2.2.5.4.2. Market
Forecast, 2021 - 2029
12.2.2.5.5. Latin
America
12.2.2.5.5.1. Market
Estimation, 2015 - 2020
12.2.2.5.5.2. Market
Forecast, 2021 - 2029
12.2.3. Hospitals
and Clinics
12.2.3.1. Definition
12.2.3.2. Market Estimation and Penetration, 2015 - 2020
12.2.3.3. Market Forecast, 2021 - 2029
12.2.3.4. Compound Annual Growth Rate (CAGR)
12.2.3.5. Regional Bifurcation
12.2.3.5.1. North
America
12.2.3.5.1.1. Market
Estimation, 2015 - 2020
12.2.3.5.1.2. Market
Forecast, 2021 - 2029
12.2.3.5.2. Europe
12.2.3.5.2.1. Market
Estimation, 2015 - 2020
12.2.3.5.2.2. Market
Forecast, 2021 - 2029
12.2.3.5.3. Asia
Pacific
12.2.3.5.3.1. Market
Estimation, 2015 - 2020
12.2.3.5.3.2. Market
Forecast, 2021 - 2029
12.2.3.5.4. Middle
East and Africa
12.2.3.5.4.1. Market
Estimation, 2015 - 2020
12.2.3.5.4.2. Market
Forecast, 2021 - 2029
12.2.3.5.5. Latin
America
12.2.3.5.5.1. Market
Estimation, 2015 - 2020
12.2.3.5.5.2. Market
Forecast, 2021 - 2029
12.2.4. Others
12.2.4.1. Definition
12.2.4.2. Market Estimation and Penetration, 2015 - 2020
12.2.4.3. Market Forecast, 2021 - 2029
12.2.4.4. Compound Annual Growth Rate (CAGR)
12.2.4.5. Regional Bifurcation
12.2.4.5.1. North
America
12.2.4.5.1.1. Market
Estimation, 2015 - 2020
12.2.4.5.1.2. Market
Forecast, 2021 - 2029
12.2.4.5.2. Europe
12.2.4.5.2.1. Market
Estimation, 2015 - 2020
12.2.4.5.2.2. Market
Forecast, 2021 - 2029
12.2.4.5.3. Asia
Pacific
12.2.4.5.3.1. Market
Estimation, 2015 - 2020
12.2.4.5.3.2. Market
Forecast, 2021 - 2029
12.2.4.5.4. Middle
East and Africa
12.2.4.5.4.1. Market
Estimation, 2015 - 2020
12.2.4.5.4.2. Market
Forecast, 2021 - 2029
12.2.4.5.5. Latin
America
12.2.4.5.5.1. Market
Estimation, 2015 - 2020
12.2.4.5.5.2. Market
Forecast, 2021 - 2029
12.3. Key
Segment for Channeling Investments
12.3.1. By
End-User
13. North America Dendritic Cell Cancer Vaccine Immunotherapy
Market Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. North
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn)
13.2. North
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.2.1. Intravenous
13.2.2. Intranodal
13.2.3. Intralymphatic
13.2.4. Intradermal
13.2.5. Subcutaneous
13.3. North
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial Phase
13.3.1. Preclinical
and Phase I
13.3.2. Phase
II
13.3.3. Phase
III
13.3.4. Late
Phase Clinical Research
13.4. North
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
13.4.1. Breast
Cancer
13.4.2. Pancreatic
Cancer
13.4.3. Oesophageal
Cancer
13.4.4. Prostate
Cancer
13.4.5. Glioblastoma
13.4.6. Colorectal
Cancer
13.4.7. Melanoma
13.4.8. Liver
Cancer
13.4.9. Renal
Cancer
13.4.10. Others
13.5. North
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.1. Adults
13.5.2. Kids
13.6. North
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By End-User
13.6.1. Research
Centres
13.6.2. Pharmaceutical
Companies
13.6.3. Hospitals
and Clinics
13.6.4. Others
13.7. North
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Country
13.7.1. U.S
13.7.1.1. U.S Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.7.1.1.1. Intravenous
13.7.1.1.2. Intranodal
13.7.1.1.3. Intralymphatic
13.7.1.1.4. Intradermal
13.7.1.1.5. Subcutaneous
13.7.1.2. U.S Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
13.7.1.2.1. Preclinical
and Phase I
13.7.1.2.2. Phase
II
13.7.1.2.3. Phase
III
13.7.1.2.4. Late
Phase Clinical Research
13.7.1.3. U.S Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue
(US$ Mn) and Forecasts, By Cancer Type
13.7.1.3.1. Breast
Cancer
13.7.1.3.2. Pancreatic
Cancer
13.7.1.3.3. Oesophageal
Cancer
13.7.1.3.4. Prostate
Cancer
13.7.1.3.5. Glioblastoma
13.7.1.3.6. Colorectal
Cancer
13.7.1.3.7. Melanoma
13.7.1.3.8. Liver
Cancer
13.7.1.3.9. Renal
Cancer
13.7.1.3.10. Others
13.7.1.4. U.S Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue
(US$ Mn) and Forecasts, By Application
13.7.1.4.1. Adults
13.7.1.4.2. Kids
13.7.1.5. U.S Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue
(US$ Mn) and Forecasts, By End-User
13.7.1.5.1. Research
Centres
13.7.1.5.2. Pharmaceutical
Companies
13.7.1.5.3. Hospitals
and Clinics
13.7.1.5.4. Others
13.7.2. Canada
13.7.2.1. Canada Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.7.2.1.1. Intravenous
13.7.2.1.2. Intranodal
13.7.2.1.3. Intralymphatic
13.7.2.1.4. Intradermal
13.7.2.1.5. Subcutaneous
13.7.2.2. Canada Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
13.7.2.2.1. Preclinical
and Phase I
13.7.2.2.2. Phase
II
13.7.2.2.3. Phase
III
13.7.2.2.4. Late
Phase Clinical Research
13.7.2.3. Canada Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
13.7.2.3.1. Breast
Cancer
13.7.2.3.2. Pancreatic
Cancer
13.7.2.3.3. Oesophageal
Cancer
13.7.2.3.4. Prostate
Cancer
13.7.2.3.5. Glioblastoma
13.7.2.3.6. Colorectal
Cancer
13.7.2.3.7. Melanoma
13.7.2.3.8. Liver
Cancer
13.7.2.3.9. Renal
Cancer
13.7.2.3.10. Others
13.7.2.4. Canada Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
13.7.2.4.1. Adults
13.7.2.4.2. Kids
13.7.2.5. Canada Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
13.7.2.5.1. Research
Centres
13.7.2.5.2. Pharmaceutical
Companies
13.7.2.5.3. Hospitals
and Clinics
13.7.2.5.4. Others
13.7.3. Mexico
13.7.3.1. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.7.3.1.1. Intravenous
13.7.3.1.2. Intranodal
13.7.3.1.3. Intralymphatic
13.7.3.1.4. Intradermal
13.7.3.1.5. Subcutaneous
13.7.3.2. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
13.7.3.2.1. Preclinical
and Phase I
13.7.3.2.2. Phase
II
13.7.3.2.3. Phase
III
13.7.3.2.4. Late
Phase Clinical Research
13.7.3.3. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
13.7.3.3.1. Breast
Cancer
13.7.3.3.2. Pancreatic
Cancer
13.7.3.3.3. Oesophageal
Cancer
13.7.3.3.4. Prostate
Cancer
13.7.3.3.5. Glioblastoma
13.7.3.3.6. Colorectal
Cancer
13.7.3.3.7. Melanoma
13.7.3.3.8. Liver
Cancer
13.7.3.3.9. Renal
Cancer
13.7.3.3.10. Others
13.7.3.4. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
13.7.3.4.1. Adults
13.7.3.4.2. Kids
13.7.3.5. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
13.7.3.5.1. Research
Centres
13.7.3.5.2. Pharmaceutical
Companies
13.7.3.5.3. Hospitals
and Clinics
13.7.3.5.4. Others
13.7.4. Rest of
North America
13.7.4.1. Rest of North America Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.7.4.1.1. Intravenous
13.7.4.1.2. Intranodal
13.7.4.1.3. Intralymphatic
13.7.4.1.4. Intradermal
13.7.4.1.5. Subcutaneous
13.7.4.2. Rest of North America Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
13.7.4.2.1. Preclinical
and Phase I
13.7.4.2.2. Phase
II
13.7.4.2.3. Phase
III
13.7.4.2.4. Late
Phase Clinical Research
13.7.4.3. Rest of North America Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
13.7.4.3.1. Breast
Cancer
13.7.4.3.2. Pancreatic
Cancer
13.7.4.3.3. Oesophageal
Cancer
13.7.4.3.4. Prostate
Cancer
13.7.4.3.5. Glioblastoma
13.7.4.3.6. Colorectal
Cancer
13.7.4.3.7. Melanoma
13.7.4.3.8. Liver
Cancer
13.7.4.3.9. Renal
Cancer
13.7.4.3.10. Others
13.7.4.4. Rest of North America Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Application
13.7.4.4.1. Adults
13.7.4.4.2. Kids
13.7.4.5. Rest of North America Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End-User
13.7.4.5.1. Research
Centres
13.7.4.5.2. Pharmaceutical
Companies
13.7.4.5.3. Hospitals
and Clinics
13.7.4.5.4. Others
13.8. Key
Segment for Channeling Investments
13.8.1. By
Country
13.8.2. By
Route of Administration
13.8.3. By
Clinical Trial Phase
13.8.4. By
Cancer Type
13.8.5. By
Application
13.8.6. By
End-User
14. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market
Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Europe
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn)
14.2. Europe
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
14.2.1. Intravenous
14.2.2. Intranodal
14.2.3. Intralymphatic
14.2.4. Intradermal
14.2.5. Subcutaneous
14.3. Europe
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial Phase
14.3.1. Preclinical
and Phase I
14.3.2. Phase
II
14.3.3. Phase
III
14.3.4. Late
Phase Clinical Research
14.4. Europe
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
14.4.1. Breast
Cancer
14.4.2. Pancreatic
Cancer
14.4.3. Oesophageal
Cancer
14.4.4. Prostate
Cancer
14.4.5. Glioblastoma
14.4.6. Colorectal
Cancer
14.4.7. Melanoma
14.4.8. Liver
Cancer
14.4.9. Renal
Cancer
14.4.10. Others
14.5. Europe
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.1. Adults
14.5.2. Kids
14.6. Europe
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By End-User
14.6.1. Research
Centres
14.6.2. Pharmaceutical
Companies
14.6.3. Hospitals
and Clinics
14.6.4. Others
14.7. Europe
Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Country
14.7.1. France
14.7.1.1. France Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.1.1.1. Intravenous
14.7.1.1.2. Intranodal
14.7.1.1.3. Intralymphatic
14.7.1.1.4. Intradermal
14.7.1.1.5. Subcutaneous
14.7.1.2. France Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
14.7.1.2.1. Preclinical
and Phase I
14.7.1.2.2. Phase
II
14.7.1.2.3. Phase
III
14.7.1.2.4. Late
Phase Clinical Research
14.7.1.3. France Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
14.7.1.3.1. Breast
Cancer
14.7.1.3.2. Pancreatic
Cancer
14.7.1.3.3. Oesophageal
Cancer
14.7.1.3.4. Prostate
Cancer
14.7.1.3.5. Glioblastoma
14.7.1.3.6. Colorectal
Cancer
14.7.1.3.7. Melanoma
14.7.1.3.8. Liver
Cancer
14.7.1.3.9. Renal
Cancer
14.7.1.3.10. Others
14.7.1.4. France Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
14.7.1.4.1. Adults
14.7.1.4.2. Kids
14.7.1.5. France Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
14.7.1.5.1. Research
Centres
14.7.1.5.2. Pharmaceutical
Companies
14.7.1.5.3. Hospitals
and Clinics
14.7.1.5.4. Others
14.7.2. The UK
14.7.2.1. The UK Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.2.1.1. Intravenous
14.7.2.1.2. Intranodal
14.7.2.1.3. Intralymphatic
14.7.2.1.4. Intradermal
14.7.2.1.5. Subcutaneous
14.7.2.2. The UK Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
14.7.2.2.1. Preclinical
and Phase I
14.7.2.2.2. Phase
II
14.7.2.2.3. Phase
III
14.7.2.2.4. Late
Phase Clinical Research
14.7.2.3. The UK Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
14.7.2.3.1. Breast
Cancer
14.7.2.3.2. Pancreatic
Cancer
14.7.2.3.3. Oesophageal
Cancer
14.7.2.3.4. Prostate
Cancer
14.7.2.3.5. Glioblastoma
14.7.2.3.6. Colorectal
Cancer
14.7.2.3.7. Melanoma
14.7.2.3.8. Liver
Cancer
14.7.2.3.9. Renal
Cancer
14.7.2.3.10. Others
14.7.2.4. The UK Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
14.7.2.4.1. Adults
14.7.2.4.2. Kids
14.7.2.5. The UK Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
14.7.2.5.1. Research
Centres
14.7.2.5.2. Pharmaceutical
Companies
14.7.2.5.3. Hospitals
and Clinics
14.7.2.5.4. Others
14.7.3. Spain
14.7.3.1. Spain Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.3.1.1. Intravenous
14.7.3.1.2. Intranodal
14.7.3.1.3. Intralymphatic
14.7.3.1.4. Intradermal
14.7.3.1.5. Subcutaneous
14.7.3.2. Spain Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
14.7.3.2.1. Preclinical
and Phase I
14.7.3.2.2. Phase
II
14.7.3.2.3. Phase
III
14.7.3.2.4. Late
Phase Clinical Research
14.7.3.3. Spain Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
14.7.3.3.1. Breast
Cancer
14.7.3.3.2. Pancreatic
Cancer
14.7.3.3.3. Oesophageal
Cancer
14.7.3.3.4. Prostate
Cancer
14.7.3.3.5. Glioblastoma
14.7.3.3.6. Colorectal
Cancer
14.7.3.3.7. Melanoma
14.7.3.3.8. Liver
Cancer
14.7.3.3.9. Renal
Cancer
14.7.3.3.10. Others
14.7.3.4. Spain Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
14.7.3.4.1. Adults
14.7.3.4.2. Kids
14.7.3.5. Spain Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
14.7.3.5.1. Research
Centres
14.7.3.5.2. Pharmaceutical
Companies
14.7.3.5.3. Hospitals
and Clinics
14.7.3.5.4. Others
14.7.4. Germany
14.7.4.1. Germany Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.4.1.1. Intravenous
14.7.4.1.2. Intranodal
14.7.4.1.3. Intralymphatic
14.7.4.1.4. Intradermal
14.7.4.1.5. Subcutaneous
14.7.4.2. Germany Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
14.7.4.2.1. Preclinical
and Phase I
14.7.4.2.2. Phase
II
14.7.4.2.3. Phase
III
14.7.4.2.4. Late
Phase Clinical Research
14.7.4.3. Germany Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
14.7.4.3.1. Breast
Cancer
14.7.4.3.2. Pancreatic
Cancer
14.7.4.3.3. Oesophageal
Cancer
14.7.4.3.4. Prostate
Cancer
14.7.4.3.5. Glioblastoma
14.7.4.3.6. Colorectal
Cancer
14.7.4.3.7. Melanoma
14.7.4.3.8. Liver
Cancer
14.7.4.3.9. Renal
Cancer
14.7.4.3.10. Others
14.7.4.4. Germany Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
14.7.4.4.1. Adults
14.7.4.4.2. Kids
14.7.4.5. Germany Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
14.7.4.5.1. Research
Centres
14.7.4.5.2. Pharmaceutical
Companies
14.7.4.5.3. Hospitals
and Clinics
14.7.4.5.4. Others
14.7.5. Italy
14.7.5.1. Italy Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.5.1.1. Intravenous
14.7.5.1.2. Intranodal
14.7.5.1.3. Intralymphatic
14.7.5.1.4. Intradermal
14.7.5.1.5. Subcutaneous
14.7.5.2. Italy Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
14.7.5.2.1. Preclinical
and Phase I
14.7.5.2.2. Phase
II
14.7.5.2.3. Phase
III
14.7.5.2.4. Late
Phase Clinical Research
14.7.5.3. Italy Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
14.7.5.3.1. Breast
Cancer
14.7.5.3.2. Pancreatic
Cancer
14.7.5.3.3. Oesophageal
Cancer
14.7.5.3.4. Prostate
Cancer
14.7.5.3.5. Glioblastoma
14.7.5.3.6. Colorectal
Cancer
14.7.5.3.7. Melanoma
14.7.5.3.8. Liver
Cancer
14.7.5.3.9. Renal
Cancer
14.7.5.3.10. Others
14.7.5.4. Italy Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
14.7.5.4.1. Adults
14.7.5.4.2. Kids
14.7.5.5. Italy Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
14.7.5.5.1. Research
Centres
14.7.5.5.2. Pharmaceutical
Companies
14.7.5.5.3. Hospitals
and Clinics
14.7.5.5.4. Others
14.7.6. Nordic
Countries
14.7.6.1. Nordic Countries Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.6.1.1. Intravenous
14.7.6.1.2. Intranodal
14.7.6.1.3. Intralymphatic
14.7.6.1.4. Intradermal
14.7.6.1.5. Subcutaneous
14.7.6.2. Nordic Countries Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
14.7.6.2.1. Preclinical
and Phase I
14.7.6.2.2. Phase
II
14.7.6.2.3. Phase
III
14.7.6.2.4. Late
Phase Clinical Research
14.7.6.3. Nordic Countries Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.7.6.3.1. Breast
Cancer
14.7.6.3.2. Pancreatic
Cancer
14.7.6.3.3. Oesophageal
Cancer
14.7.6.3.4. Prostate
Cancer
14.7.6.3.5. Glioblastoma
14.7.6.3.6. Colorectal
Cancer
14.7.6.3.7. Melanoma
14.7.6.3.8. Liver
Cancer
14.7.6.3.9. Renal
Cancer
14.7.6.3.10. Others
14.7.6.4. Nordic Countries Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Application
14.7.6.4.1. Adults
14.7.6.4.2. Kids
14.7.6.5. Nordic Countries Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By End-User
14.7.6.5.1. Research
Centres
14.7.6.5.2. Pharmaceutical
Companies
14.7.6.5.3. Hospitals
and Clinics
14.7.6.5.4. Others
14.7.6.6. Nordic Countries Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux
Union
14.7.7.1. Benelux Union Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.7.1.1. Intravenous
14.7.7.1.2. Intranodal
14.7.7.1.3. Intralymphatic
14.7.7.1.4. Intradermal
14.7.7.1.5. Subcutaneous
14.7.7.2. Benelux Union Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
14.7.7.2.1. Preclinical
and Phase I
14.7.7.2.2. Phase
II
14.7.7.2.3. Phase
III
14.7.7.2.4. Late
Phase Clinical Research
14.7.7.3. Benelux Union Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.7.7.3.1. Breast
Cancer
14.7.7.3.2. Pancreatic
Cancer
14.7.7.3.3. Oesophageal
Cancer
14.7.7.3.4. Prostate
Cancer
14.7.7.3.5. Glioblastoma
14.7.7.3.6. Colorectal
Cancer
14.7.7.3.7. Melanoma
14.7.7.3.8. Liver
Cancer
14.7.7.3.9. Renal
Cancer
14.7.7.3.10. Others
14.7.7.4. Benelux Union Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Application
14.7.7.4.1. Adults
14.7.7.4.2. Kids
14.7.7.5. Benelux Union Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By End-User
14.7.7.5.1. Research
Centres
14.7.7.5.2. Pharmaceutical
Companies
14.7.7.5.3. Hospitals
and Clinics
14.7.7.5.4. Others
14.7.7.6. Benelux Union Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The
Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of
Europe
14.7.8.1. Rest of Europe Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.8.1.1. Intravenous
14.7.8.1.2. Intranodal
14.7.8.1.3. Intralymphatic
14.7.8.1.4. Intradermal
14.7.8.1.5. Subcutaneous
14.7.8.2. Rest of Europe Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
14.7.8.2.1. Preclinical
and Phase I
14.7.8.2.2. Phase
II
14.7.8.2.3. Phase
III
14.7.8.2.4. Late
Phase Clinical Research
14.7.8.3. Rest of Europe Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.7.8.3.1. Breast
Cancer
14.7.8.3.2. Pancreatic
Cancer
14.7.8.3.3. Oesophageal
Cancer
14.7.8.3.4. Prostate
Cancer
14.7.8.3.5. Glioblastoma
14.7.8.3.6. Colorectal
Cancer
14.7.8.3.7. Melanoma
14.7.8.3.8. Liver
Cancer
14.7.8.3.9. Renal
Cancer
14.7.8.3.10. Others
14.7.8.4. Rest of Europe Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Application
14.7.8.4.1. Adults
14.7.8.4.2. Kids
14.7.8.5. Rest of Europe Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By End-User
14.7.8.5.1. Research
Centres
14.7.8.5.2. Pharmaceutical
Companies
14.7.8.5.3. Hospitals
and Clinics
14.7.8.5.4. Others
14.8. Key
Segment for Channeling Investments
14.8.1. By
Country
14.8.2. By
Route of Administration
14.8.3. By
Clinical Trial Phase
14.8.4. By
Cancer Type
14.8.5. By
Application
14.8.6. By
End-User
15. Asia Pacific Dendritic Cell Cancer Vaccine Immunotherapy
Market Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Asia
Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn)
15.2. Asia
Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.2.1. Intravenous
15.2.2. Intranodal
15.2.3. Intralymphatic
15.2.4. Intradermal
15.2.5. Subcutaneous
15.3. Asia
Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial Phase
15.3.1. Preclinical
and Phase I
15.3.2. Phase
II
15.3.3. Phase
III
15.3.4. Late
Phase Clinical Research
15.4. Asia
Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
15.4.1. Breast
Cancer
15.4.2. Pancreatic
Cancer
15.4.3. Oesophageal
Cancer
15.4.4. Prostate
Cancer
15.4.5. Glioblastoma
15.4.6. Colorectal
Cancer
15.4.7. Melanoma
15.4.8. Liver
Cancer
15.4.9. Renal
Cancer
15.4.10. Others
15.5. Asia
Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Application
15.5.1. Adults
15.5.2. Kids
15.6. Asia
Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By End-User
15.6.1. Research
Centres
15.6.2. Pharmaceutical
Companies
15.6.3. Hospitals
and Clinics
15.6.4. Others
15.7. Asia
Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Country
15.7.1. China
15.7.1.1. China Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.1.1.1. Intravenous
15.7.1.1.2. Intranodal
15.7.1.1.3. Intralymphatic
15.7.1.1.4. Intradermal
15.7.1.1.5. Subcutaneous
15.7.1.2. China Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
15.7.1.2.1. Preclinical
and Phase I
15.7.1.2.2. Phase
II
15.7.1.2.3. Phase
III
15.7.1.2.4. Late
Phase Clinical Research
15.7.1.3. China Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
15.7.1.3.1. Breast
Cancer
15.7.1.3.2. Pancreatic
Cancer
15.7.1.3.3. Oesophageal
Cancer
15.7.1.3.4. Prostate
Cancer
15.7.1.3.5. Glioblastoma
15.7.1.3.6. Colorectal
Cancer
15.7.1.3.7. Melanoma
15.7.1.3.8. Liver
Cancer
15.7.1.3.9. Renal
Cancer
15.7.1.3.10. Others
15.7.1.4. China Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.1.4.1. Adults
15.7.1.4.2. Kids
15.7.1.5. China Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
15.7.1.5.1. Research
Centres
15.7.1.5.2. Pharmaceutical
Companies
15.7.1.5.3. Hospitals
and Clinics
15.7.1.5.4. Others
15.7.2. Japan
15.7.2.1. Japan Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.2.1.1. Intravenous
15.7.2.1.2. Intranodal
15.7.2.1.3. Intralymphatic
15.7.2.1.4. Intradermal
15.7.2.1.5. Subcutaneous
15.7.2.2. Japan Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
15.7.2.2.1. Preclinical
and Phase I
15.7.2.2.2. Phase
II
15.7.2.2.3. Phase
III
15.7.2.2.4. Late
Phase Clinical Research
15.7.2.3. Japan Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
15.7.2.3.1. Breast
Cancer
15.7.2.3.2. Pancreatic
Cancer
15.7.2.3.3. Oesophageal
Cancer
15.7.2.3.4. Prostate
Cancer
15.7.2.3.5. Glioblastoma
15.7.2.3.6. Colorectal
Cancer
15.7.2.3.7. Melanoma
15.7.2.3.8. Liver
Cancer
15.7.2.3.9. Renal
Cancer
15.7.2.3.10. Others
15.7.2.4. Japan Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.2.4.1. Adults
15.7.2.4.2. Kids
15.7.2.5. Japan Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
15.7.2.5.1. Research
Centres
15.7.2.5.2. Pharmaceutical
Companies
15.7.2.5.3. Hospitals
and Clinics
15.7.2.5.4. Others
15.7.3. India
15.7.3.1. India Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.3.1.1. Intravenous
15.7.3.1.2. Intranodal
15.7.3.1.3. Intralymphatic
15.7.3.1.4. Intradermal
15.7.3.1.5. Subcutaneous
15.7.3.2. India Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
15.7.3.2.1. Preclinical
and Phase I
15.7.3.2.2. Phase
II
15.7.3.2.3. Phase
III
15.7.3.2.4. Late
Phase Clinical Research
15.7.3.3. India Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
15.7.3.3.1. Breast
Cancer
15.7.3.3.2. Pancreatic
Cancer
15.7.3.3.3. Oesophageal
Cancer
15.7.3.3.4. Prostate
Cancer
15.7.3.3.5. Glioblastoma
15.7.3.3.6. Colorectal
Cancer
15.7.3.3.7. Melanoma
15.7.3.3.8. Liver
Cancer
15.7.3.3.9. Renal
Cancer
15.7.3.3.10. Others
15.7.3.4. India Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.3.4.1. Adults
15.7.3.4.2. Kids
15.7.3.5. India Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
15.7.3.5.1. Research
Centres
15.7.3.5.2. Pharmaceutical
Companies
15.7.3.5.3. Hospitals
and Clinics
15.7.3.5.4. Others
15.7.4. New
Zealand
15.7.4.1. New Zealand Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.4.1.1. Intravenous
15.7.4.1.2. Intranodal
15.7.4.1.3. Intralymphatic
15.7.4.1.4. Intradermal
15.7.4.1.5. Subcutaneous
15.7.4.2. New Zealand Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
15.7.4.2.1. Preclinical
and Phase I
15.7.4.2.2. Phase
II
15.7.4.2.3. Phase
III
15.7.4.2.4. Late
Phase Clinical Research
15.7.4.3. New Zealand Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
15.7.4.3.1. Breast
Cancer
15.7.4.3.2. Pancreatic
Cancer
15.7.4.3.3. Oesophageal
Cancer
15.7.4.3.4. Prostate
Cancer
15.7.4.3.5. Glioblastoma
15.7.4.3.6. Colorectal
Cancer
15.7.4.3.7. Melanoma
15.7.4.3.8. Liver
Cancer
15.7.4.3.9. Renal
Cancer
15.7.4.3.10. Others
15.7.4.4. New Zealand Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.4.4.1. Adults
15.7.4.4.2. Kids
15.7.4.5. New Zealand Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
15.7.4.5.1. Research
Centres
15.7.4.5.2. Pharmaceutical
Companies
15.7.4.5.3. Hospitals
and Clinics
15.7.4.5.4. Others
15.7.5. Australia
15.7.5.1. Australia Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.5.1.1. Intravenous
15.7.5.1.2. Intranodal
15.7.5.1.3. Intralymphatic
15.7.5.1.4. Intradermal
15.7.5.1.5. Subcutaneous
15.7.5.2. Australia Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
15.7.5.2.1. Preclinical
and Phase I
15.7.5.2.2. Phase
II
15.7.5.2.3. Phase
III
15.7.5.2.4. Late
Phase Clinical Research
15.7.5.3. Australia Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
15.7.5.3.1. Breast
Cancer
15.7.5.3.2. Pancreatic
Cancer
15.7.5.3.3. Oesophageal
Cancer
15.7.5.3.4. Prostate
Cancer
15.7.5.3.5. Glioblastoma
15.7.5.3.6. Colorectal
Cancer
15.7.5.3.7. Melanoma
15.7.5.3.8. Liver
Cancer
15.7.5.3.9. Renal
Cancer
15.7.5.3.10. Others
15.7.5.4. Australia Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.5.4.1. Adults
15.7.5.4.2. Kids
15.7.5.5. Australia Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
15.7.5.5.1. Research
Centres
15.7.5.5.2. Pharmaceutical
Companies
15.7.5.5.3. Hospitals
and Clinics
15.7.5.5.4. Others
15.7.6. South
Korea
15.7.6.1. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.6.1.1. Intravenous
15.7.6.1.2. Intranodal
15.7.6.1.3. Intralymphatic
15.7.6.1.4. Intradermal
15.7.6.1.5. Subcutaneous
15.7.6.2. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
15.7.6.2.1. Preclinical
and Phase I
15.7.6.2.2. Phase
II
15.7.6.2.3. Phase
III
15.7.6.2.4. Late
Phase Clinical Research
15.7.6.3. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
15.7.6.3.1. Breast
Cancer
15.7.6.3.2. Pancreatic
Cancer
15.7.6.3.3. Oesophageal
Cancer
15.7.6.3.4. Prostate
Cancer
15.7.6.3.5. Glioblastoma
15.7.6.3.6. Colorectal
Cancer
15.7.6.3.7. Melanoma
15.7.6.3.8. Liver
Cancer
15.7.6.3.9. Renal
Cancer
15.7.6.3.10. Others
15.7.6.4. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.6.4.1. Adults
15.7.6.4.2. Kids
15.7.6.5. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
15.7.6.5.1. Research
Centres
15.7.6.5.2. Pharmaceutical
Companies
15.7.6.5.3. Hospitals
and Clinics
15.7.6.5.4. Others
15.7.7. Southeast
Asia
15.7.7.1. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.7.1.1. Intravenous
15.7.7.1.2. Intranodal
15.7.7.1.3. Intralymphatic
15.7.7.1.4. Intradermal
15.7.7.1.5. Subcutaneous
15.7.7.2. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
15.7.7.2.1. Preclinical
and Phase I
15.7.7.2.2. Phase
II
15.7.7.2.3. Phase
III
15.7.7.2.4. Late
Phase Clinical Research
15.7.7.3. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.7.7.3.1. Breast
Cancer
15.7.7.3.2. Pancreatic
Cancer
15.7.7.3.3. Oesophageal
Cancer
15.7.7.3.4. Prostate
Cancer
15.7.7.3.5. Glioblastoma
15.7.7.3.6. Colorectal
Cancer
15.7.7.3.7. Melanoma
15.7.7.3.8. Liver
Cancer
15.7.7.3.9. Renal
Cancer
15.7.7.3.10. Others
15.7.7.4. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Application
15.7.7.4.1. Adults
15.7.7.4.2. Kids
15.7.7.5. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By End-User
15.7.7.5.1. Research
Centres
15.7.7.5.2. Pharmaceutical
Companies
15.7.7.5.3. Hospitals
and Clinics
15.7.7.5.4. Others
15.7.7.6. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest
of Southeast Asia
15.7.8. Rest of
Asia Pacific
15.7.8.1. Rest of Asia Pacific Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.8.1.1. Intravenous
15.7.8.1.2. Intranodal
15.7.8.1.3. Intralymphatic
15.7.8.1.4. Intradermal
15.7.8.1.5. Subcutaneous
15.7.8.2. Rest of Asia Pacific Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
15.7.8.2.1. Preclinical
and Phase I
15.7.8.2.2. Phase
II
15.7.8.2.3. Phase
III
15.7.8.2.4. Late
Phase Clinical Research
15.7.8.3. Rest of Asia Pacific Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.7.8.3.1. Breast
Cancer
15.7.8.3.2. Pancreatic
Cancer
15.7.8.3.3. Oesophageal
Cancer
15.7.8.3.4. Prostate
Cancer
15.7.8.3.5. Glioblastoma
15.7.8.3.6. Colorectal
Cancer
15.7.8.3.7. Melanoma
15.7.8.3.8. Liver
Cancer
15.7.8.3.9. Renal
Cancer
15.7.8.3.10. Others
15.7.8.4. Rest of Asia Pacific Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Application
15.7.8.4.1. Adults
15.7.8.4.2. Kids
15.7.8.5. Rest of Asia Pacific Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End-User
15.7.8.5.1. Research
Centres
15.7.8.5.2. Pharmaceutical
Companies
15.7.8.5.3. Hospitals
and Clinics
15.7.8.5.4. Others
15.8. Key
Segment for Channeling Investments
15.8.1. By
Country
15.8.2. By
Route of Administration
15.8.3. By
Clinical Trial Phase
15.8.4. By
Cancer Type
15.8.5. By
Application
15.8.6. By
End-User
16. Middle East and Africa Dendritic Cell Cancer Vaccine
Immunotherapy Market Analysis and Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Middle
East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$
Mn)
16.2. Middle
East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$
Mn) and Forecasts, By Route of Administration
16.2.1. Intravenous
16.2.2. Intranodal
16.2.3. Intralymphatic
16.2.4. Intradermal
16.2.5. Subcutaneous
16.3. Middle
East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
16.3.1. Preclinical
and Phase I
16.3.2. Phase
II
16.3.3. Phase
III
16.3.4. Late
Phase Clinical Research
16.4. Middle
East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$
Mn) and Forecasts, By Cancer Type
16.4.1. Breast
Cancer
16.4.2. Pancreatic
Cancer
16.4.3. Oesophageal
Cancer
16.4.4. Prostate
Cancer
16.4.5. Glioblastoma
16.4.6. Colorectal
Cancer
16.4.7. Melanoma
16.4.8. Liver
Cancer
16.4.9. Renal
Cancer
16.4.10. Others
16.5. Middle
East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$
Mn) and Forecasts, By Application
16.5.1. Adults
16.5.2. Kids
16.6. Middle
East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$
Mn) and Forecasts, By End-User
16.6.1. Research
Centres
16.6.2. Pharmaceutical
Companies
16.6.3. Hospitals
and Clinics
16.6.4. Others
16.7. Middle
East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$
Mn) and Forecasts, By Country
16.7.1. Saudi
Arabia
16.7.1.1. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.1.1.1. Intravenous
16.7.1.1.2. Intranodal
16.7.1.1.3. Intralymphatic
16.7.1.1.4. Intradermal
16.7.1.1.5. Subcutaneous
16.7.1.2. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
16.7.1.2.1. Preclinical
and Phase I
16.7.1.2.2. Phase
II
16.7.1.2.3. Phase
III
16.7.1.2.4. Late
Phase Clinical Research
16.7.1.3. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.7.1.3.1. Breast
Cancer
16.7.1.3.2. Pancreatic
Cancer
16.7.1.3.3. Oesophageal
Cancer
16.7.1.3.4. Prostate
Cancer
16.7.1.3.5. Glioblastoma
16.7.1.3.6. Colorectal
Cancer
16.7.1.3.7. Melanoma
16.7.1.3.8. Liver
Cancer
16.7.1.3.9. Renal
Cancer
16.7.1.3.10. Others
16.7.1.4. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Application
16.7.1.4.1. Adults
16.7.1.4.2. Kids
16.7.1.5. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By End-User
16.7.1.5.1. Research
Centres
16.7.1.5.2. Pharmaceutical
Companies
16.7.1.5.3. Hospitals
and Clinics
16.7.1.5.4. Others
16.7.2. UAE
16.7.2.1. UAE Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
16.7.2.1.1. Intravenous
16.7.2.1.2. Intranodal
16.7.2.1.3. Intralymphatic
16.7.2.1.4. Intradermal
16.7.2.1.5. Subcutaneous
16.7.2.2. UAE Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
16.7.2.2.1. Preclinical
and Phase I
16.7.2.2.2. Phase
II
16.7.2.2.3. Phase
III
16.7.2.2.4. Late
Phase Clinical Research
16.7.2.3. UAE Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue
(US$ Mn) and Forecasts, By Cancer Type
16.7.2.3.1. Breast
Cancer
16.7.2.3.2. Pancreatic
Cancer
16.7.2.3.3. Oesophageal
Cancer
16.7.2.3.4. Prostate
Cancer
16.7.2.3.5. Glioblastoma
16.7.2.3.6. Colorectal
Cancer
16.7.2.3.7. Melanoma
16.7.2.3.8. Liver
Cancer
16.7.2.3.9. Renal
Cancer
16.7.2.3.10. Others
16.7.2.4. UAE Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue
(US$ Mn) and Forecasts, By Application
16.7.2.4.1. Adults
16.7.2.4.2. Kids
16.7.2.5. UAE Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue
(US$ Mn) and Forecasts, By End-User
16.7.2.5.1. Research
Centres
16.7.2.5.2. Pharmaceutical
Companies
16.7.2.5.3. Hospitals
and Clinics
16.7.2.5.4. Others
16.7.3. Egypt
16.7.3.1. Egypt Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.3.1.1. Intravenous
16.7.3.1.2. Intranodal
16.7.3.1.3. Intralymphatic
16.7.3.1.4. Intradermal
16.7.3.1.5. Subcutaneous
16.7.3.2. Egypt Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
16.7.3.2.1. Preclinical
and Phase I
16.7.3.2.2. Phase
II
16.7.3.2.3. Phase
III
16.7.3.2.4. Late
Phase Clinical Research
16.7.3.3. Egypt Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
16.7.3.3.1. Breast
Cancer
16.7.3.3.2. Pancreatic
Cancer
16.7.3.3.3. Oesophageal
Cancer
16.7.3.3.4. Prostate
Cancer
16.7.3.3.5. Glioblastoma
16.7.3.3.6. Colorectal
Cancer
16.7.3.3.7. Melanoma
16.7.3.3.8. Liver
Cancer
16.7.3.3.9. Renal
Cancer
16.7.3.3.10. Others
16.7.3.4. Egypt Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
16.7.3.4.1. Adults
16.7.3.4.2. Kids
16.7.3.5. Egypt Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
16.7.3.5.1. Research
Centres
16.7.3.5.2. Pharmaceutical
Companies
16.7.3.5.3. Hospitals
and Clinics
16.7.3.5.4. Others
16.7.4. Kuwait
16.7.4.1. Kuwait Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.4.1.1. Intravenous
16.7.4.1.2. Intranodal
16.7.4.1.3. Intralymphatic
16.7.4.1.4. Intradermal
16.7.4.1.5. Subcutaneous
16.7.4.2. Kuwait Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
16.7.4.2.1. Preclinical
and Phase I
16.7.4.2.2. Phase
II
16.7.4.2.3. Phase
III
16.7.4.2.4. Late
Phase Clinical Research
16.7.4.3. Kuwait Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
16.7.4.3.1. Breast
Cancer
16.7.4.3.2. Pancreatic
Cancer
16.7.4.3.3. Oesophageal
Cancer
16.7.4.3.4. Prostate
Cancer
16.7.4.3.5. Glioblastoma
16.7.4.3.6. Colorectal
Cancer
16.7.4.3.7. Melanoma
16.7.4.3.8. Liver
Cancer
16.7.4.3.9. Renal
Cancer
16.7.4.3.10. Others
16.7.4.4. Kuwait Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
16.7.4.4.1. Adults
16.7.4.4.2. Kids
16.7.4.5. Kuwait Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
16.7.4.5.1. Research
Centres
16.7.4.5.2. Pharmaceutical
Companies
16.7.4.5.3. Hospitals
and Clinics
16.7.4.5.4. Others
16.7.5. South
Africa
16.7.5.1. South Africa Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.5.1.1. Intravenous
16.7.5.1.2. Intranodal
16.7.5.1.3. Intralymphatic
16.7.5.1.4. Intradermal
16.7.5.1.5. Subcutaneous
16.7.5.2. South Africa Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
16.7.5.2.1. Preclinical
and Phase I
16.7.5.2.2. Phase
II
16.7.5.2.3. Phase
III
16.7.5.2.4. Late
Phase Clinical Research
16.7.5.3. South Africa Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.7.5.3.1. Breast
Cancer
16.7.5.3.2. Pancreatic
Cancer
16.7.5.3.3. Oesophageal
Cancer
16.7.5.3.4. Prostate
Cancer
16.7.5.3.5. Glioblastoma
16.7.5.3.6. Colorectal
Cancer
16.7.5.3.7. Melanoma
16.7.5.3.8. Liver
Cancer
16.7.5.3.9. Renal
Cancer
16.7.5.3.10. Others
16.7.5.4. South Africa Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By Application
16.7.5.4.1. Adults
16.7.5.4.2. Kids
16.7.5.5. South Africa Dendritic Cell Cancer Vaccine Immunotherapy
Market Revenue (US$ Mn) and Forecasts, By End-User
16.7.5.5.1. Research
Centres
16.7.5.5.2. Pharmaceutical
Companies
16.7.5.5.3. Hospitals
and Clinics
16.7.5.5.4. Others
16.7.6. Rest of
Middle East & Africa
16.7.6.1. Rest of Middle East & Africa Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.6.1.1. Intravenous
16.7.6.1.2. Intranodal
16.7.6.1.3. Intralymphatic
16.7.6.1.4. Intradermal
16.7.6.1.5. Subcutaneous
16.7.6.2. Rest of Middle East & Africa Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
16.7.6.2.1. Preclinical
and Phase I
16.7.6.2.2. Phase
II
16.7.6.2.3. Phase
III
16.7.6.2.4. Late
Phase Clinical Research
16.7.6.3. Rest of Middle East & Africa Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.7.6.3.1. Breast
Cancer
16.7.6.3.2. Pancreatic
Cancer
16.7.6.3.3. Oesophageal
Cancer
16.7.6.3.4. Prostate
Cancer
16.7.6.3.5. Glioblastoma
16.7.6.3.6. Colorectal
Cancer
16.7.6.3.7. Melanoma
16.7.6.3.8. Liver
Cancer
16.7.6.3.9. Renal
Cancer
16.7.6.3.10. Others
16.7.6.4. Rest of Middle East & Africa Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Application
16.7.6.4.1. Adults
16.7.6.4.2. Kids
16.7.6.5. Rest of Middle East & Africa Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End-User
16.7.6.5.1. Research
Centres
16.7.6.5.2. Pharmaceutical
Companies
16.7.6.5.3. Hospitals
and Clinics
16.7.6.5.4. Others
16.8. Key
Segment for Channeling Investments
16.8.1. By
Country
16.8.2. By Route
of Administration
16.8.3. By
Clinical Trial Phase
16.8.4. By
Cancer Type
16.8.5. By
Application
16.8.6. By
End-User
17. Latin America Dendritic Cell Cancer Vaccine Immunotherapy
Market Analysis and Forecasts, 2021 - 2029
17.1. Overview
17.1.1. Latin
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn)
17.2. Latin
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
17.2.1. Intravenous
17.2.2. Intranodal
17.2.3. Intralymphatic
17.2.4. Intradermal
17.2.5. Subcutaneous
17.3. Latin
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial Phase
17.3.1. Preclinical
and Phase I
17.3.2. Phase
II
17.3.3. Phase
III
17.3.4. Late
Phase Clinical Research
17.4. Latin
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
17.4.1. Breast
Cancer
17.4.2. Pancreatic
Cancer
17.4.3. Oesophageal
Cancer
17.4.4. Prostate
Cancer
17.4.5. Glioblastoma
17.4.6. Colorectal
Cancer
17.4.7. Melanoma
17.4.8. Liver
Cancer
17.4.9. Renal
Cancer
17.4.10. Others
17.5. Latin
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Application
17.5.1. Adults
17.5.2. Kids
17.6. Latin
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By End-User
17.6.1. Research
Centres
17.6.2. Pharmaceutical
Companies
17.6.3. Hospitals
and Clinics
17.6.4. Others
17.7. Latin
America Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue (US$ Mn) and
Forecasts, By Country
17.7.1. Brazil
17.7.1.1. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
17.7.1.1.1. Intravenous
17.7.1.1.2. Intranodal
17.7.1.1.3. Intralymphatic
17.7.1.1.4. Intradermal
17.7.1.1.5. Subcutaneous
17.7.1.2. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
17.7.1.2.1. Preclinical
and Phase I
17.7.1.2.2. Phase
II
17.7.1.2.3. Phase
III
17.7.1.2.4. Late
Phase Clinical Research
17.7.1.3. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue
(US$ Mn) and Forecasts, By Cancer Type
17.7.1.3.1. Breast
Cancer
17.7.1.3.2. Pancreatic
Cancer
17.7.1.3.3. Oesophageal
Cancer
17.7.1.3.4. Prostate
Cancer
17.7.1.3.5. Glioblastoma
17.7.1.3.6. Colorectal
Cancer
17.7.1.3.7. Melanoma
17.7.1.3.8. Liver
Cancer
17.7.1.3.9. Renal
Cancer
17.7.1.3.10. Others
17.7.1.4. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
17.7.1.4.1. Adults
17.7.1.4.2. Kids
17.7.1.5. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
17.7.1.5.1. Research
Centres
17.7.1.5.2. Pharmaceutical
Companies
17.7.1.5.3. Hospitals
and Clinics
17.7.1.5.4. Others
17.7.2. Argentina
17.7.2.1. Argentina Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
17.7.2.1.1. Intravenous
17.7.2.1.2. Intranodal
17.7.2.1.3. Intralymphatic
17.7.2.1.4. Intradermal
17.7.2.1.5. Subcutaneous
17.7.2.2. Argentina Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
17.7.2.2.1. Preclinical
and Phase I
17.7.2.2.2. Phase
II
17.7.2.2.3. Phase
III
17.7.2.2.4. Late
Phase Clinical Research
17.7.2.3. Argentina Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
17.7.2.3.1. Breast
Cancer
17.7.2.3.2. Pancreatic
Cancer
17.7.2.3.3. Oesophageal
Cancer
17.7.2.3.4. Prostate
Cancer
17.7.2.3.5. Glioblastoma
17.7.2.3.6. Colorectal
Cancer
17.7.2.3.7. Melanoma
17.7.2.3.8. Liver
Cancer
17.7.2.3.9. Renal
Cancer
17.7.2.3.10. Others
17.7.2.4. Argentina Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By Application
17.7.2.4.1. Adults
17.7.2.4.2. Kids
17.7.2.5. Argentina Dendritic Cell Cancer Vaccine Immunotherapy Market
Revenue (US$ Mn) and Forecasts, By End-User
17.7.2.5.1. Research
Centres
17.7.2.5.2. Pharmaceutical
Companies
17.7.2.5.3. Hospitals
and Clinics
17.7.2.5.4. Others
17.7.3. Rest of
Latin America
17.7.3.1. Rest of Latin America Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route of Administration
17.7.3.1.1. Intravenous
17.7.3.1.2. Intranodal
17.7.3.1.3. Intralymphatic
17.7.3.1.4. Intradermal
17.7.3.1.5. Subcutaneous
17.7.3.2. Rest of Latin America Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
17.7.3.2.1. Preclinical
and Phase I
17.7.3.2.2. Phase
II
17.7.3.2.3. Phase
III
17.7.3.2.4. Late
Phase Clinical Research
17.7.3.3. Rest of Latin America Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
17.7.3.3.1. Breast
Cancer
17.7.3.3.2. Pancreatic
Cancer
17.7.3.3.3. Oesophageal
Cancer
17.7.3.3.4. Prostate
Cancer
17.7.3.3.5. Glioblastoma
17.7.3.3.6. Colorectal
Cancer
17.7.3.3.7. Melanoma
17.7.3.3.8. Liver
Cancer
17.7.3.3.9. Renal
Cancer
17.7.3.3.10. Others
17.7.3.4. Rest of Latin America Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Application
17.7.3.4.1. Adults
17.7.3.4.2. Kids
17.7.3.5. Rest of Latin America Dendritic Cell Cancer Vaccine
Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End-User
17.7.3.5.1. Research
Centres
17.7.3.5.2. Pharmaceutical
Companies
17.7.3.5.3. Hospitals
and Clinics
17.7.3.5.4. Others
17.8. Key
Segment for Channeling Investments
17.8.1. By
Country
17.8.2. By
Route of Administration
17.8.3. By
Clinical Trial Phase
17.8.4. By
Cancer Type
17.8.5. By Application
17.8.6. By
End-User
18. Competitive Benchmarking
18.1. Brand
Benchmarking
18.2. Market
Share Analysis, 2020
18.3. Global
Presence and Growth Strategies
18.3.1. Mergers
and Acquisitions
18.3.2. Product
Launches
18.3.3. Investments
Trends
18.3.4. R&D
Initiatives
19. Player Profiles
19.1. Activartis
GmbH
19.1.1. Company
Details
19.1.2. Company
Overview
19.1.3. Product
Offerings
19.1.4. Key
Developments
19.1.5. Financial
Analysis
19.1.6. SWOT
Analysis
19.1.7. Business
Strategies
19.2. Bellicum Pharmaceuticals
19.2.1. Company
Details
19.2.2. Company
Overview
19.2.3. Product
Offerings
19.2.4. Key
Developments
19.2.5. Financial
Analysis
19.2.6. SWOT
Analysis
19.2.7. Business
Strategies
19.3. Dendreon Corporation
19.3.1. Company
Details
19.3.2. Company
Overview
19.3.3. Product
Offerings
19.3.4. Key
Developments
19.3.5. Financial
Analysis
19.3.6. SWOT
Analysis
19.3.7. Business
Strategies
19.4. Elios Therapeutics
19.4.1. Company
Details
19.4.2. Company
Overview
19.4.3. Product
Offerings
19.4.4. Key Developments
19.4.5. Financial
Analysis
19.4.6. SWOT
Analysis
19.4.7. Business
Strategies
19.5. Immunicum AB
19.5.1. Company
Details
19.5.2. Company
Overview
19.5.3. Product
Offerings
19.5.4. Key
Developments
19.5.5. Financial
Analysis
19.5.6. SWOT
Analysis
19.5.7. Business
Strategies
19.6. Immunicum AB
19.6.1. Company
Details
19.6.2. Company
Overview
19.6.3. Product
Offerings
19.6.4. Key
Developments
19.6.5. Financial
Analysis
19.6.6. SWOT
Analysis
19.6.7. Business
Strategies
19.7. JW Creagene
19.7.1. Company
Details
19.7.2. Company
Overview
19.7.3. Product
Offerings
19.7.4. Key
Developments
19.7.5. Financial
Analysis
19.7.6. SWOT
Analysis
19.7.7. Business
Strategies
19.8. Medigene AG
19.8.1. Company
Details
19.8.2. Company
Overview
19.8.3. Product
Offerings
19.8.4. Key
Developments
19.8.5. Financial
Analysis
19.8.6. SWOT
Analysis
19.8.7. Business
Strategies
19.9. THERAVECTYS
19.9.1. Company
Details
19.9.2. Company
Overview
19.9.3. Product
Offerings
19.9.4. Key
Developments
19.9.5. Financial
Analysis
19.9.6. SWOT
Analysis
19.9.7. Business
Strategies
19.10. Other
Market Participants
20. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
